Informed SkinTranexamic Acid

Products

Tranexamic Acid

Tranexamic acid (TXA)

Emerging topical and oral treatment for melasma and post-inflammatory hyperpigmentation

HyperpigmentationDark Spots
Safe for skin types
Safe forAll Fitzpatrick types I–VI
Avoid ifNone related to Fitzpatrick type

Tranexamic acid inhibits plasmin-mediated melanocyte activation and is particularly beneficial for Fitzpatrick IV–VI, where melasma and post-inflammatory hyperpigmentation are more prevalent. It is one of the best-evidenced brightening agents for darker skin types because it lacks the irritation and atrophy risks associated with long-term hydroquinone use.

In plain English

A brightening active that works by interrupting the signal that tells skin cells to produce excess melanin. Effective for melasma (the hormonal brown patches common in pregnancy or with oral contraceptives) and post-inflammatory hyperpigmentation. Available both as a topical serum (OTC, low risk) and as an oral prescription (more powerful, requires monitoring). One of the best-evidenced newer options for pigmentation in darker skin types.

Top-rated products

Sourced via EWG Skin Deep, one of the scientific databases used by the Yuka app to evaluate cosmetic ingredient safety.

Discoloration Correcting Serum

Good Molecules

Clearly Corrective Dark Spot Solution

Kiehl's

Even Tone Super Glow Serum

Topicals

The science

Tranexamic acid (TXA) inhibits plasmin-mediated activation of melanocytes, reducing UV-induced and hormonally-driven melanin synthesis. It was originally a haemostatic drug used systemically in surgery. Its application to melasma and post-inflammatory hyperpigmentation emerged from case observations of brightening side effects in dermatology patients taking it orally for other conditions. Topical TXA (2-5%) and oral TXA (250mg twice daily) have both been studied in RCTs for melasma. The oral route carries a theoretical thromboembolic risk that limits it to short courses under medical supervision.

Why these scores
Medical PromiseHigher is better
7/10

Double-blind RCTs show 49.5% MASI score reduction at 12 weeks for oral TXA (Lee et al. 2016, n=74); topical shows comparable efficacy to hydroquinone in split-face studies with better tolerability.

Short-term SafetyHigher is safer
9/10

Topical form has excellent safety profile; oral form carries theoretical clotting risk at prescribed dermatological doses (250mg BID) but no documented adverse events in dermatology trial populations.

Long-term SafetyHigher is safer
8/10

Topical long-term use appears safe in the published literature; oral long-term use beyond 3 months is not well-studied for this specific indication.

Should You Try ThisHigher is better
7/10

Excellent option particularly for darker skin types where other brightening agents carry higher side effect risk.

Common misconceptions
Myth

Tranexamic acid is the same as hydroquinone.

Reality

Different mechanism and safety profile. TXA has no reported skin atrophy risk or ochronosis risk associated with long-term hydroquinone use. The evidence quality for TXA is growing but hydroquinone has a larger historical evidence base.

Myth

All tranexamic acid products work the same way.

Reality

Topical and oral TXA have different pharmacokinetics and different evidence profiles. A 10% topical serum does not deliver the same systemic concentration as 250mg oral twice daily.

What the evidence firmly supports
  • 49.5% MASI reduction with oral TXA vs 17.5% placebo (Lee et al. 2016 RCT, n=74).

  • Comparable efficacy to hydroquinone topically with fewer side effects; mechanism confirmed via plasmin-melanocyte pathway inhibition.

Still being studied
  • ?

    Optimal topical concentration (2% vs 5% vs 10%).

  • ?

    Long-term oral safety at dermatological doses beyond 3 months.

  • ?

    Combination with niacinamide and vitamin C for additive brightening effect.

Key Study

Tranexamic acid as a novel treatment for melasma

Lee et al. · Journal of the European Academy of Dermatology and Venereology · 2016

A double-blind RCT (n=74) comparing oral tranexamic acid 250mg twice daily to placebo for 12 weeks found significantly greater reductions in MASI (Melasma Area Severity Index) scores vs. placebo (49.5% vs 17.5%). Topical 2-5% TXA serums show comparable efficacy to hydroquinone in split-face studies with fewer side effects.

PubMed ↗  PMID 41403744
Products on the market
BrandManufacturerWhat differentiates itApprovalPricing
The Ordinary Tranexamic Acid 10%DECIEMHigh-concentration OTC serum; accessible price point for trying TXA topicallyOTC$17
SkinCeuticals Discoloration DefenseSkinCeuticalsContains 3% tranexamic acid plus 10% kojic acid; clinically studied combinationOTC$108
Murad Rapid Dark Spot Correcting SerumMuradOTC with TXA and glycolic acid; targets both melanin production and surface exfoliationOTC$76
Prescription oral tranexamic acid 250mgGenericRx-only; systemic route for moderate-to-severe melasma under medical supervisionRx (off-label for melasma)$30-60/month
Quick Facts
DurationTopical: daily use, results in 8-12 weeks; oral: 3 months
Studies60+
FDA StatusOTC cosmetic ingredient (topical); Rx (oral, off-label for melasma)
Price$15-$80 serum (topical); $30-$60/month (oral Rx)

Should You Try This?

15107OUT OF 10

Probably okay to try

Questions to ask your doctor

  • Q1

    Am I a candidate for oral vs topical tranexamic acid given my melasma severity?

    Good answer

    A good answer assesses MASI score and explains when the oral form adds benefit over topical, typically for moderate-to-severe melasma that has not responded adequately to topical treatment.

  • Q2

    What is the recommended course length and what monitoring do you conduct?

    Good answer

    A good answer specifies typically 3 months for oral TXA, with awareness of any clotting risk factors and a clear rationale for the duration.

  • Q3

    Are there contraindications given my personal or family health history?

    Good answer

    A good answer screens for personal or family history of deep vein thrombosis, pulmonary embolism, or clotting disorders before prescribing oral TXA.

Clinic checklist

Universal

  • Check the practitioner is licensed and registered. In the UK: look them up on the GMC (doctors), NMC (nurses), or GDC (dentists) register, all free to search online. In the US: search your state medical board. Takes 2 minutes. If they cannot tell you their regulatory body, leave.
  • Ask to see the product box before treatment. It should be factory-sealed with a visible lot number and expiry date. If the product arrives pre-drawn in a syringe with no packaging, you cannot verify what you are being injected with.
  • You should receive a written consent form before treatment. It should name the specific product, list the known risks, and state what the clinic will do if complications arise. A single generic form with no product name is not adequate.
  • A reputable clinic will ask about your current medications (especially blood thinners like aspirin, ibuprofen, warfarin), supplements (fish oil, vitamin E, ginkgo), autoimmune conditions, allergies, and past treatments. If no one asks, they are skipping a safety step.
  • Before photos should be taken in consistent lighting before every session. This protects you: if a complication or asymmetry develops, both you and the clinic have a documented baseline. If a clinic does not take before photos, they are not tracking outcomes.
  • Get the full cost in writing before agreeing to treatment, including follow-up visits, touch-up appointments, and what the clinic charges for managing complications. Verbal quotes are not binding.

Procedure-specific

  • Check that topical TXA concentration is at least 2% for meaningful efficacy; concentrations below this are not supported by clinical trial evidence.
  • Store topical TXA products out of direct sunlight; TXA degrades with UV exposure.
  • Combine with daily SPF 50+ -- TXA prevents melanin production but SPF prevents the UV trigger that drives melanin synthesis.
  • TXA can be layered with niacinamide for additive brightening effect.
  • For oral form only: confirm Rx from a dermatologist and screen for any personal clotting risk factors before starting.

Educational content only. This page summarises published clinical research and is not medical advice. Consult a qualified healthcare provider before making decisions about your care.

Researched by

Val Yermakova

Informed Girl · informedgirl.com